Regeneron begins phase III trial of COVID-19 treatment in U.K.

By The Science Advisory Board staff writers

September 14, 2020 -- Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.

The Recovery open-label study is one of the largest COVID-19 trials in the world, according to Regeneron. It will compare the effectiveness of Regeneron's REGN-COV2 antibody therapy to the standard of care in patients hospitalized with COVID-19.

REGN-COV2 is also being evaluated in two other phase II and phase III trials to treat COVID-19 and prevent COVID-19 transmission among household members, according to Regeneron.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.